Identifying predictors for comorbidities related mortality versus pancreatic cancer related mortality in patients with intraductal papillary mucinous neoplasm

Katsunori Sekine; Naoyoshi Nagata; Yuya Hisada; Kenjiro Yamamoto; Shuntaro Mukai; Takayoshi Tsuchiya; Akihiro Machitori; Yasushi Kojima; Tomoyuki Yada; Natsuyo Yamamoto; Naomi Uemura; Takao Itoi; Takashi Kawai

doi:10.1002/ueg2.12540

Identifying predictors for comorbidities related mortality versus pancreatic cancer related mortality in patients with intraductal papillary mucinous neoplasm

United European Gastroenterol J. 2024 Feb 17. doi: 10.1002/ueg2.12540. Online ahead of print.

Authors

Affiliations

¹ Department of Gastroenterology and Hepatology, National Center for Global Health and Medicine, Kohnodai Hospital, Ichikawa, Chiba, Japan.
² Department of Gastroenterological Endoscopy, Tokyo Medical University, Tokyo, Japan.
³ Department of Gastroenterology and Hepatology, National Center for Global Health and Medicine, Tokyo, Japan.
⁴ Department of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo, Japan.
⁵ Department of Radiology, National Center for Global Health and Medicine, Kohnodai Hospital, Ichikawa, Chiba, Japan.

PMID: 38367226
DOI: 10.1002/ueg2.12540

Abstract

Backgrounds: Few data are available for surveillance decisions focusing on factors related to mortality, as the primary outcome, in intraductal papillary mucinous neoplasm (IPMN) patients.

Aims: We aimed to identify imaging features and patient backgrounds associated with mortality risks by comparing pancreatic cancer (PC) and comorbidities.

Methods: We retrospectively conducted a multicenter long-term follow-up of 1864 IPMN patients. Competing risk analysis was performed for PC- and comorbidity-related mortality.

Results: During the median follow-up period of 5.5 years, 14.0% (261/1864) of patients died. Main pancreatic duct ≥5 mm and mural nodules were significantly related to all-cause and PC-related mortality, whereas cyst ≥30 mm did not relate. In 1730 patients without high-risk imaging features, 48 and 180 patients died of PC and comorbidity. In the derivation cohort, a prediction model for comorbidity-related mortality was created, comprising age, cancer history, diabetes mellitus complications, chronic heart failure, stroke, paralysis, peripheral artery disease, liver cirrhosis, and collagen disease in multivariate analysis. If a patient had a 5 score, 5- and 10-year comorbidity-related mortality is estimated at 18.9% and 50.2%, respectively, more than 7 times higher than PC-related mortality. The model score was also significantly associated with comorbidity-related mortality in a validation cohort.

Conclusions: This study demonstrates main pancreatic duct dilation and mural nodules indicate risk of PC-related mortality, identifying patients who need periodic examination. A comorbidity-related mortality prediction model based on the patient's age and comorbidities can stratify patients who do not require regular tests, especially beyond 5 years, among IPMN patients without high-risk features.

Clinical trial registration: T2022-0046.

Keywords: IPMN; intraductal papillary mucinous neoplasm; long-term cohort study; mortality prediction model; pancreatic cancer; pancreatic duct.

Abstract

Grants and funding